Point72 Asset Management
NRIX icon

Point72 Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Point72 Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.96M Sell
449,106
-2,762,574
-86% -$45.8M 0.01% 1476
2025
Q4 		$60.9M Buy
3,211,680
+340,183
+12% +$4.89M 0.07% 329
2025
Q3 		$26.5M Sell
2,871,497
-832,097
-22% -$8.64M 0.04% 455
2025
Q2 		$42.2M Buy
3,703,594
+3,485,141
+1,595% +$37.7M 0.08% 280
2025
Q1 		$2.6M Sell
218,453
-654,506
-75% -$10.9M 0.01% 1163
2024
Q4 		$16.4M Buy
+872,959
New +$20M 0.04% 525
2024
Q2 		– Sell
-9,500
Closed -$140K – 2274
2024
Q1 		$140K Buy
+9,500
New +$102K ﹤0.01% 1960
2023
Q4 		– Sell
-1,114
Closed -$8.76K – 2602
2023
Q3 		$8.76K Buy
1,114
+1,107
+15,814% +$10.1K ﹤0.01% 2341
2023
Q2 		$67 Sell
7
-9,594
-100% -$97.8K ﹤0.01% 2072
2023
Q1 		$85.3K Buy
+9,601
New +$100K ﹤0.01% 1662
2022
Q2 		– Sell
-69,850
Closed -$979K – 1559
2022
Q1 		$979K Sell
69,850
-66,700
-49% -$1.18M ﹤0.01% 964
2021
Q4 		$3.95M Buy
+136,550
New +$4.14M 0.02% 719

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Point72 Asset Management's NRIX Position: Q1 2026 in Review

Point72 Asset Management reduced its Nurix Therapeutics (NRIX) stake by 86% in Q1 2026, selling an estimated $45.8M and leaving 449,106 shares worth $6.96M. The position accounts for 0.01% of the portfolio, ranked #1476.

Point72 Asset Management first reported a position in NRIX in Q4 2021 and has held it in 12 quarters since. The position peaked at $60.9M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Point72 Asset Management held 449,106 shares of Nurix Therapeutics worth $6.96M as of Q1 2026.
  • Point72 Asset Management sold 2,762,574 Nurix Therapeutics shares in Q1 2026, an estimated $45.8M.
  • Nurix Therapeutics made up 0.01% of Point72 Asset Management's portfolio in Q1 2026, its #1476 holding.
  • Point72 Asset Management first reported a position in Nurix Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • Point72 Asset Management's Nurix Therapeutics position peaked at $60.9M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.